HTX-019 via 2-min injection or 30-min infusion in healthy subjects

9Citations
Citations of this article
30Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aim: HTX-019 (CINVANTI® [aprepitant injectable emulsion]) is a neurokinin 1 receptor antagonist approved for preventing acute and delayed chemotherapy-induced nausea and vomiting (CINV). HTX-019 is free of polysorbate 80 and other synthetic surfactants and showed bioequivalence to and a more favorable safety profile than fosaprepitant when administered as a 30-min infusion in healthy subjects. The shortage of small-volume parenteral solutions led to a recommendation to administer HTX-019 by intravenous push. The objectives were to evaluate pharmacokinetics, tolerability and safety following HTX-019 administration by injection versus infusion. Materials & methods: Study comprised Part A, a pilot Phase I, single-center, randomized, pharmacokinetic, safety and tolerability, open-label study, followed by Part B, a two-sequence crossover study of HTX-019 130 mg in healthy adults, via injection and infusion. Blood samples were evaluated for aprepitant pharmacokinetics and bioequivalence. Safety evaluations included treatment-emergent adverse events (TEAEs), vital signs, clinical laboratory testing and electrocardiograms. Results: In Part A, 24 subjects were randomly assigned to three cohorts (n = 8 per cohort) and received HTX-019 130 mg, administered intravenously over 15 min (cohort 1), 5 min (cohort 2) or 2 min (cohort 3). Progression to Part B occurred after acceptable tolerability was established in cohorts 2 and 3. In Part B, 50 randomized subjects received a 2-min injection (9 ml/min) and 30-min infusion (296 ml/h) of HTX-019 130 mg. Bioequivalence was demonstrated for HTX-019 injection and infusion. Both administration methods via a peripheral line were well tolerated; eight subjects experienced 11 TEAEs (six related) following injection and nine experienced 14 TEAEs (nine related) following infusion. Headache and fatigue were the most prevalent treatment-related TEAEs; one subject per group experienced feeling hot ≤30 min after drug administration. Conclusion: Pharmacokinetic and tolerability profiles of 2-min HTX-019 injection support this potential alternative administration method for CINV prevention. © 2018 2018 Thomas Ottoboni. Lay abstract This study assesses the management of a common side effect of chemotherapy, known as chemotherapy-induced nausea and vomiting (CINV), and addresses a major shortage of small-volume solutions and intravenous bags used to deliver treatment to prevent CINV. Although effective treatments to prevent CINV are available, a high percentage of patients with cancer receiving chemotherapy still experience this side effect. HTX-019, an injectable emulsion of aprepitant, was approved in 2017 as a 30-min infusion to prevent CINV associated with chemotherapy. In November 2017, US FDA announced a shortage of small-volume parenteral solutions, including those used in administering HTX-019. The American Society of Health-System Pharmacists recommended switching the delivery of treatments by infusion to iv. push (injection over 5 min or less) whenever possible. In this study, HTX-019 130 mg given as a 2-min injection was comparable in effectiveness and safety to the 30-min infusion, and both methods of administration were well tolerated. These findings confirm the short injection as an alternative method of administering HTX-019 to prevent CINV, reducing the need for iv. bags.

Cite

CITATION STYLE

APA

Ottoboni, T., Lauw, M., Keller, M. R., Cravets, M., Manhard, K., Clendeninn, N., & Quart, B. (2019). HTX-019 via 2-min injection or 30-min infusion in healthy subjects. Future Oncology, 15(8), 865–874. https://doi.org/10.2217/fon-2018-0809

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free